Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients benefit from ICIs, and whether the magnitude of benefit is specific factor-dependent remains unclear. We performed a systematic review to improve our understanding of clinicopathologic and biomolecular features associated with improved survival upon treatment with ICIs for NSCLC.

Methods

We searched PubMed, Web of Science, Embase, and Scopus from database inception to August 31, 2021, for randomized controlled trials (RCTs) comparing overall survival (OS) in NSCLC treated with ICIs vs control therapies. We calculated the pooled OS hazard ratio (HR) and 95% CI in subgroups using a random-effects model, and asses

SUBMITTER: Yang F 

PROVIDER: S-EPMC9425065 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature